Truth in science.
Transformation in medicine.
At Vera Therapeutics, we pursue truth in science to transform medicine in autoimmune diseases, starting with the kidney.
Rigorous science
We focus on upstream immune pathways that drive disease, asking hard questions and following the evidence.
Patient-centered
We listen closely to patients and caregivers, so their experiences help shape how we approach disease, not just how we measure it.
Designed with intention
Vera Therapeutics was designed to think long term, with independent and disciplined focus on the work that meaningful progress requires.
OUR FOCUS
Committed to IgA nephropathy
We are deeply focused on IgA nephropathy, where the immune drivers of disease remain largely unaddressed and patient need is high.
FEATURED news
July 7, 2026
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
- TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).
- The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.
- Investor webcast is scheduled for July 7 at 4:30 pm EDT.
Built on truth, driven by science
We challenge long-standing assumptions in nephrology by combining rigorous science with a deep respect for the lived experience to turn discovery into meaningful progress.
Patient stories
We listen to the lived experiences of people affected by disease. Their perspectives help shape how we pursue new approaches and measure progress.
Working at Vera Therapeutics
We move with purpose, uphold scientific rigor, and value the perspectives that help us see the whole human experience behind complex disease.
Investor & Media Relations
Access our investor and media relations center for company news, financial information, and resources for analysts and journalists.